Texas EXperimental Cancer Therapeutics Network - TEX CTN
德克萨斯实验癌症治疗网络 - TEX CTN
基本信息
- 批准号:10784849
- 负责人:
- 金额:$ 195.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-14 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:Advanced DevelopmentAdverse eventAuthorshipBiochemicalBiologicalBiopsyCancer CenterClinicClinicalClinical ResearchClinical TrialsClinical Trials DesignClinical Trials NetworkCollaborationsCommon NeoplasmCritical PathwaysDNADataDevelopmentDiagnosticDiseaseDoseDose LimitingEnrollmentEnsureEnvironmentEthnic PopulationExplosionFacultyGoalsHair follicle structureHealthHumanImageImmuneInstitutionInternationalInterventionInvestigational TherapiesJointsLeadLeadershipMalignant NeoplasmsMedicalMentorsMinority GroupsMolecularMolecular AbnormalityMolecular AnalysisMolecular ProfilingNeoplasm Circulating CellsNew AgentsOncologyOrganizational AffiliationPathologicPathologistPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacodynamicsPhasePopulationPositioning AttributeProcessProteinsProtocols documentationPublicationsQualifyingRNAReportingResearch DesignResearch PersonnelResistanceRural PopulationSafetySamplingScheduleSkinSpecimenTechnologyTestingTexasTherapeuticTherapeutic AgentsTherapeutic Clinical TrialTherapeutic UsesTissuesTranslatingTumor MarkersUniversitiesUniversity of Texas M D Anderson Cancer Centeraustinbiomarker drivencancer health disparitycarcinogenesiscirculating DNAcirculating biomarkersclinical practiceclinically relevantcytokineearly phase clinical trialearly-career facultyimaging modalityinnovationmeetingsmembermultidisciplinarynovelnovel markernovel therapeuticspatient derived xenograft modelpharmacodynamic biomarkerpharmacokinetics and pharmacodynamicspre-clinicalprecision oncologypredicting responsepredictive markerprospectiveprotocol developmentracial populationradiologistrational designresponseresponse biomarkersafety studytargeted agenttranslational scientisttumorunderserved minority
项目摘要
Project Summary
The Texas Experimental Cancer Therapeutic Network (TEX-CTN) is comprised of the University
of Texas MD Anderson Cancer Center (UT MDACC; Lead Academic Organization, LAO), the UT
Health San Antonio Cancer Center (UT Health SA; Affiliate Organization, AO), the UT at Austin
(UTA); Affiliate Organization, AO) and the UT Medical Branch at Galveston (UTMB; Affiliate
Organization, AO). We propose to advance the development of novel therapeutics using precision
oncology approaches and rationally designed clinical trials. The long-term objective is to provide
the ETCTN with the joint expertise of the faculty from the four member institutions, expediting
translating preclinical discoveries to the clinic, and to provide significant scientific and
administrative leadership to the ETCTN. Our hypothesis for the optimal development of novel
targeted agents includes testing within a molecularly profiled population, integrating
pharmacodynamics markers in early clinical trials and programmatic assessment of predictors of
intrinsic sensitivity/resistance and mechanisms of acquired resistance. We are proposing to
achieve these goals through the following five specific aims: 1) To study, in an efficient, systematic
and collaborative manner, the safety and clinical activity of new agents or hypothesis-driven novel
combinations. 2) To molecularly profile tumors and patients (host tissues), to optimize selection
of potentially relevant therapies based on the molecular aberrations identified in the tumor and
immune environment, where appropriate. 3) To develop and validate clinically relevant of
predictors and pharmacodynamic markers of response. 4) To mentor early career faculty, trainees
and research personnel in the leadership, conduct, analysis, and reporting of ETCTN trials. 5) To
provide scientific and administrative leadership within ETCTN. The TEX-CTN will unite four
University of Texas institutions to facilitate access to novel therapies and biomarker-driven trials
across the network, for patients with rare as well as common tumors, as well as patients from
underserved minority populations. Our team consists of internationally recognized leaders of
Phase I and II trials, multidisciplinary disease experts, interventional radiologists, translational
pathologists, and diagnostic radiologists. TEX-CTN is well poised to attain a new paradigm for
early experimental therapeutic clinical trials.
项目摘要
德克萨斯州实验癌症治疗网络(TEX-CTN)由德克萨斯大学
德克萨斯州医学博士安德森癌症中心(UT MDACC;领导学术组织,LAO),UT
健康圣安东尼奥癌症中心(UT Health SA; Affiliate Organization,AO),UT在奥斯汀
(UTA); Affiliate Organization,AO)和位于加尔维斯顿的UT Medical分支(UTMB; Affiliate
组织,AO)。我们建议使用精确度来推进新疗法的开发
肿瘤学方法和合理设计的临床试验。长期目标是提供
ETCTN与来自四个成员机构的教师的联合专业知识,加快
将临床前发现转化为临床,并提供重要的科学和
行政领导向东。我们关于小说最佳发展的假设
靶向药物包括在分子分布的群体中进行测试,
早期临床试验中的药效学标志物和
内在敏感性/抗性和获得性抗性机制。我们建议
通过以下五个具体目标来实现这些目标:1)以有效的,系统的
和合作的方式,安全性和临床活性的新药或假设驱动的新的
组合。2)对肿瘤和患者(宿主组织)进行分子分析,以优化选择
基于肿瘤中确定的分子畸变的潜在相关治疗,
免疫环境,在适当的情况下。3)开发并验证临床相关的
反应的预测因子和药效学标志物。4)指导早期职业教师,学员
领导、开展、分析和报告ETCTN试验的研究人员。5)到
在ETCTN内提供科学和行政领导。TEX-CTN将联合四个
德克萨斯大学机构促进获得新疗法和生物标志物驱动的试验
在整个网络中,对于罕见和常见肿瘤患者,以及来自
服务不足的少数民族。我们的团队由国际公认的领导者组成,
I期和II期试验,多学科疾病专家,介入放射科医生,翻译
病理学家和放射诊断学家。TEX-CTN已做好准备,以实现一个新的范例,
早期实验性治疗临床试验。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
mTOR 抑制剂在现实世界的患有转移性前列腺癌和 PI3K 通路改变的患者队列中的有效性和持久性。
- DOI:10.1038/s41391-022-00612-8
- 发表时间:2023
- 期刊:
- 影响因子:4.8
- 作者:Eule,CorbinJ;Flaig,ThomasW;Wong,Katy;Graf,Ryon;Lam,ElaineT
- 通讯作者:Lam,ElaineT
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
- DOI:10.1038/s41598-021-90500-3
- 发表时间:2021-06-09
- 期刊:
- 影响因子:4.6
- 作者:Haines E;Nishida Y;Carr MI;Montoya RH;Ostermann LB;Zhang W;Zenke FT;Blaukat A;Andreeff M;Vassilev LT
- 通讯作者:Vassilev LT
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Capasso其他文献
Anna Capasso的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 195.2万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 195.2万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 195.2万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 195.2万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 195.2万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 195.2万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 195.2万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 195.2万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 195.2万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 195.2万 - 项目类别: